Timothy Vreeland

6PUBLICATIONS
10CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 03, 2023
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis.

Elizabeth Lee Carpenter, Spencer Van Decar, Alexandra M Adams

|Jan 22, 2022
Contemporary Assessment of Need for Palliative Bypass After Aborted Pancreatoduodenectomy Following Neoadjuvant Therapy.

Timothy J Vreeland, Phillip M Kemp Bohan, Timothy E Newhook

|May 13, 2021
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.

Robert C Chick, Mark B Faries, Diane F Hale

|Jan 30, 2021
Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression.

Phillip M Kemp Bohan, Robert C Chick, Anne E O'Shea

|Feb 20, 2020
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer.

G Travis Clifton, Diane Hale, Timothy J Vreeland

|Jul 06, 2019
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.

Tommy A Brown, Kevin Byrd, Timothy J Vreeland

Pageof 1

Frequent Collaborators

4 joint publications

Guy T Clifton

2 joint publications

Robert C Chick

1 joint publications

Rashmi K Murthy

1 joint publications

Phillip M Kemp Bohan